Key Drivers
- Strong Liquidity
- Equity Funded
- Ongoing Losses
AIAI Summary
ODTX is now a well-funded, single-asset clinical bet: its $433M cash runway limits near-term dilution, but its ~$600M pipeline valuation requires OD-001's promising Phase 2a ulcerative-colitis results to reproduce in Phase 2b. Investors should prioritize upcoming trial initiation and confirmation of remission, durability, and safety, as a failed readout would undermine the company's core valuation thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Equity Funded
- •Ongoing Losses
ODTX's equity financing has created a strong liquidity cushion and modest leverage, but persistent losses, negative cash flow, and no meaningful revenue keep execution risk high.
Price Behavior
Key Price Behavior Insights:
- •Volatile rebound
- •Key resistance
- •Fragile support
ODTX is volatile and fragile, rebounding from $21.99 but needing to clear $24.60–$24.70 and $25.04 to improve, while a drop below $23.10 would turn bearish.
Sharp rebound from $21.99 to $24.38 in three trading days
Sentiment & News
Key News Insights:
- •Conference Participation
- •Investor Engagement
- •No Pipeline Updates
Odyssey Therapeutics is increasing investor and healthcare outreach through September conference appearances, with no new clinical, regulatory, or corporate catalysts disclosed.
The news is neutral for Odyssey, improving visibility but offering no material fundamental catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings